

**Table I. Cumulative Cancer Risk to Age 70 in Individuals with Lynch Syndrome**

| <b>Cancer</b>       | <b><i>MLH1</i></b> | <b><i>MSH2</i></b> | <b><i>MSH6</i></b> | <b><i>PMS2</i></b> |
|---------------------|--------------------|--------------------|--------------------|--------------------|
| Colon               | 41-58%             | 48-51%             | 10-22%             | 15-20%             |
| Endometrium         | 29-54%             | 21-24%             | 8-32%              | 15%                |
| Ovary               | 6-20%              | 8-24%              | 1-11%              | **                 |
| Stomach             | 6-11%              | 0.2-8%             | ≤3%                | **                 |
| Urinary tract       | 0.2-3%             | 2-4%               | <1%                | **                 |
| Small bowel         | 0.4-5%             | 1.1-1.3%           | Not reported       | **                 |
| Brain/CNS           | 0.3-2%             | 3-6%               | Not reported       | **                 |
| Hepatobiliary tract | 2-3%               | 0.02-0.4%          | Not reported       | **                 |
| Sebaceous neoplasms | 1-9%*              | 1-9%*              | Not reported       | Not reported       |
| Pancreas            | 1-6%*              | 1-6%*              | Not reported       | Not reported       |

\*Risk estimate includes patients with *MLH1* and/or *MLH2* mutations

\*\*6% combined cumulative risk for renal pelvis, stomach, ovary, small bowel, ureter, brain

Barrow E, Robinson L, Alduai, W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clinical Genetics* 75:141-149, 2009.

Barrow E, Alduaij W, Robinson L, et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. *Clinical Genetics* 74:233-242, 2008.

Bonadona V, Bonaiti B, Olschwang S, et al: Cancer risks associated with germline mutations in *MLH1*, *MSH2*, and *MSH6* genes in Lynch syndrome. *JAMA* 305:2304-2310, 2011.

National Comprehensive Cancer Network: NCCN Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal V.1.2014. Available at [www.nccn.org](http://www.nccn.org)

Senter L, Clendenning M, Sotamaa K, et al: The clinical phenotype of Lynch syndrome due to germ-line *PMS2* mutations. *Gastroenterology* 135:419-428, 2008.

Watson P, Vasen HF, Meckli, J, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *International Journal of Cancer* 123:444-449, 2008.